Premature Ejaculation Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Premature ejaculation (PE) is the most common male sexual dysfunction globally, affecting 20–30% of men across all age groups. The International Society of Sexual Medicine (ISSM) defines PE as: ejaculation occurring within approximately 1 minute of vaginal penetration (lifelong/primary PE) or a clinically significant reduction in ejaculatory latency with associated distress (acquired PE), measured by the intravaginal ejaculatory latency time (IELT).

Four subtypes are recognized: lifelong (primary) PE — present since first sexual experience, has a neurobiological basis involving hypersensitivity of serotonin (5-HT) receptors that regulate ejaculatory reflex threshold; acquired PE — develops after a period of normal sexual function, often secondary to erectile dysfunction, prostatitis, hyperthyroidism, or psychosocial factors; variable PE — inconsistent early ejaculation, usually situational; subjective PE — normal or extended IELT but persistent perception of ejaculating too quickly without objective dysfunction.

Treatment is stratified by subtype and severity. Behavioral techniques (stop-start method, squeeze technique) address the psychophysiological component and build ejaculatory control. Pharmacological options include dapoxetine (Priligy) — the only on-demand SSRI specifically approved for PE in multiple countries — and daily-use SSRIs (paroxetine, sertraline, fluoxetine) that exert ejaculatory delay through serotonin reuptake inhibition at spinal ejaculatory centers. Topical anesthetics (lidocaine/prilocaine cream or spray — EMLA, Promescent, Fortacin aerosol) reduce penile sensation and delay ejaculation locally. PDE5 inhibitors (sildenafil, tadalafil) are useful when PE co-exists with erectile dysfunction. Psychosexual therapy addresses psychological, relationship, and performance anxiety factors. Combination treatment is generally superior to any single modality.

PE treatment is indicated for all subtypes meeting diagnostic criteria with associated patient or partner bother and distress. Lifelong premature ejaculation — IELT consistently under 1 minute since sexual debut — has the strongest evidence base for pharmacological treatment, particularly daily SSRIs, given its neurobiological underpinning. Dapoxetine (on-demand) is effective across all PE subtypes.

Acquired premature ejaculation requires identification and treatment of the underlying cause. When PE develops secondary to erectile dysfunction (the most common comorbidity), men often rush to ejaculate before losing their erection; PDE5 inhibitors addressing the ED frequently resolve the PE concurrently. Prostatitis-associated PE is treated with alpha-blockers (tamsulosin) and antibiotics where indicated, which reduces sympathetic nervous system hyperactivity in the pelvic floor. Hyperthyroidism-induced PE normalizes with thyroid treatment. Anxiety-related and performance anxiety PE responds well to psychosexual therapy, often combined with short-term pharmacotherapy to rebuild sexual confidence.

Post-surgical PE may emerge after pelvic or urological procedures. Relationship-specific PE (present only with certain partners or in certain situations) is predominantly psychogenic and responds to psychosexual or couples therapy. The Premature Ejaculation Diagnostic Tool (PEDT) — a validated 5-item questionnaire — guides severity assessment and treatment selection and is recommended in clinical guidelines for structured evaluation.

Eligibility for PE treatment begins with confirming the diagnosis using validated instruments. An IELT under 2 minutes with associated distress and relationship impact confirms significant PE warranting treatment. The PEDT score of ≥11 indicates probable PE, score 9–10 suggests possible PE. Patient-reported outcomes — IELT stopwatch measurement or patient estimate, degree of ejaculatory control, and personal and partner distress — guide treatment urgency and modality selection.

Workup should rule out comorbid conditions: International Index of Erectile Function (IIEF) questionnaire to assess concurrent ED; thyroid-stimulating hormone (TSH) to exclude hyperthyroidism; prostate symptom score (IPSS) and urinalysis to exclude prostatitis or lower urinary tract symptoms; psychological assessment for anxiety, depression, or relationship conflict.

Dapoxetine eligibility: men 18–64 years, confirmed PE diagnosis, taken 1–3 hours before anticipated sexual activity. Contraindicated in men with: hepatic impairment, severe renal impairment, cardiovascular disease (prolonged QT, cardiac failure, heart block), concurrent MAOIs (serious serotonin syndrome risk), concurrent thioridazine, lithium, or strong CYP3A4 inhibitors (ketoconazole, ritonavir — increase dapoxetine plasma levels dramatically). Orthostatic hypotension and syncope risk requires counselling — patients should be sitting or lying when first taking dapoxetine. Daily SSRI eligibility: adults without psychiatric contraindications; awareness of sexual side effects including anorgasmia and libido reduction. Topical anesthetics: men without known lidocaine or prilocaine allergy; use with condom to prevent partner numbness.

PE management is multimodal, combining behavioural, pharmacological, and topical approaches based on PE subtype (lifelong vs. acquired, psychological vs. neurobiological):

• Behavioural techniques: The squeeze technique (Masters and Johnson) — stimulation to near-ejaculation threshold, then partner squeezes the coronal ridge for 20 seconds until urgency subsides, repeated progressively to build ejaculatory control. The stop-start technique (Semans method) uses interruptions rather than manual compression. Sensate focus exercises reduce performance anxiety and improve interoceptive awareness. These techniques are most effective for psychogenic PE and should be practiced 2–3 times weekly for 8–12 weeks.
• Topical anaesthetics: Lidocaine-prilocaine cream (EMLA) or lidocaine 4% spray (Promescent, Stud 100) applied to the glans 15–30 minutes before intercourse reduces penile sensitivity without affecting partner sensation when used with a condom. Intravenous lidocaine spray (Promescent) with minimal transfer has the best evidence base. IELT (intravaginal ejaculation latency time) improvements of 4–6-fold are reported.
• Dapoxetine (on-demand SSRI): The only SSRI specifically approved for PE (licensed in EU, Australia, India; not FDA-approved in USA). A short-acting selective serotonin reuptake inhibitor taken 1–3 hours before intercourse, dapoxetine 30–60 mg increases IELT by 2.5–3-fold in phase III trials. Side effects include nausea (20%), dizziness, and orthostatic hypotension (avoid in syncopal patients).
• Daily SSRI therapy: Off-label use of paroxetine (most potent), sertraline, fluoxetine, or clomipramine taken daily produces ejaculation delay via central serotonergic sensitization. Effect develops over 2–3 weeks; paroxetine 20–40 mg increases IELT by 7–9-fold in meta-analyses. Used for lifelong PE and when continuous treatment is preferred over on-demand dosing.
• Tramadol on-demand: The weak opioid tramadol 50–100 mg taken 2 hours pre-intercourse has demonstrated IELT improvement in RCTs. Potential for dependence limits its use to second-line when SSRIs and dapoxetine fail. Not recommended for patients with substance use history.
• PDE5 inhibitor combination: In men with concurrent ED and PE, combining dapoxetine with a PDE5 inhibitor addresses both conditions and may extend time to ejaculation by reducing performance anxiety related to erection maintenance.
• Surgical option — selective dorsal neurectomy: Partial severing of dorsal penile nerves to reduce glans sensitivity. Controversial, not recommended by major guidelines due to irreversibility and risk of permanent sensory loss.

Dapoxetine 30 mg and 60 mg demonstrate consistent, well-documented efficacy in large randomized controlled trials. In phase III registration trials, dapoxetine extended IELT from a baseline of approximately 0.9 minutes to 3.1 minutes (30 mg) and 3.6 minutes (60 mg), representing a 3–4x increase in ejaculatory latency versus baseline and a 2–3x increase versus placebo. Patient-reported outcomes show 56–74% of men rate ejaculatory control as 'good' or 'very good' with dapoxetine 60 mg versus 19% on placebo. The on-demand dosing allows treatment only when desired, with no requirement for daily medication, and onset of effect in 1–2 hours.

Daily paroxetine (10–40 mg) produces the greatest IELT delay of any oral agent — 8–10 fold increase in IELT from baseline — and is considered the most efficacious SSRI for PE in systematic reviews, though not specifically licensed for PE in most countries. Sertraline (50–200 mg daily) produces 6–8x IELT extension; fluoxetine (20–40 mg daily) 4–6x. Effects develop over 1–2 weeks and are sustained with continued use.

Topical anesthetics (lidocaine/prilocaine cream, Fortacin aerosol) extend IELT by 5–6 fold in controlled trials with good tolerability when used with a condom to prevent partner anesthesia. Combination approaches — dapoxetine plus behavioral therapy — achieve 70–80% of men reporting good ejaculatory control, significantly superior to either alone. PDE5 inhibitors added for concurrent ED frequently normalize ejaculatory function. Psychosexual therapy produces sustained improvements in ejaculatory control, sexual satisfaction, and relationship quality in 50–70% of men with psychogenic PE.

Dapoxetine has a specific and manageable side-effect profile as the shortest-acting SSRI (half-life 1.5 hours). Most common adverse events in clinical trials: nausea (11–20%), dizziness (5–10%), headache (6–12%), and dry mouth (3–5%). These are dose-dependent and typically mild and transient. The most serious acute risk is orthostatic hypotension and syncope — occurring in approximately 0.06% of patients in trials — which is managed by taking the first dose while seated, avoiding alcohol, and ensuring adequate hydration. Serotonin syndrome risk exists when dapoxetine is combined with other serotonergic agents (SNRIs, tramadol, triptans, linezolid, St John's Wort) — absolute contraindication with MAOIs.

Daily SSRIs for PE produce the full spectrum of SSRI side effects: sexual dysfunction (reduced libido, anorgasmia, delayed orgasm — paradoxical worsening in some men), emotional blunting, insomnia or somnolence, weight gain with long-term use, and risk of antidepressant discontinuation syndrome if stopped abruptly. Patients must taper off daily SSRIs rather than stopping suddenly. Baseline psychiatric assessment is warranted.

Topical anesthetics risk partner genital numbness — this is avoided by using the product 20–30 minutes before intercourse and then applying a condom before intercourse. Hypersensitivity or allergic contact dermatitis to lidocaine/prilocaine is possible. Excessive penile anesthesia may result in loss of erection due to absent sensory input in men relying on tactile stimulation. Metered-dose Fortacin aerosol (licenced EU) has lower systemic absorption than cream formulations. No serious long-term complications are associated with PE treatments.

PE treatment response is assessed using validated patient-reported outcomes and partner feedback:

• IELT measurement: Baseline and follow-up IELT (intravaginal ejaculation latency time) measured with a stopwatch, with a clinically meaningful response defined as doubling of baseline IELT or achievement of ≥2 minutes.
• Patient-reported outcomes: The Premature Ejaculation Diagnostic Tool (PEDT) and the Index of Premature Ejaculation (IPE) are used at baseline and 8–12 weeks of treatment to quantify symptom burden and distress reduction.
• First follow-up at 4–6 weeks: Assessment of technique compliance, medication tolerability, and partner satisfaction. Dose adjustment of dapoxetine or daily SSRI if insufficient response.
• Partner involvement: Including the sexual partner in follow-up consultations significantly improves outcomes in behavioural therapy and ensures accurate IELT reporting. Relationship dynamics contributing to PE should be addressed through psychosexual therapy referral.
• Long-term management: For lifelong (primary) PE, long-term pharmacotherapy is often required. For acquired PE, addressing the underlying trigger (new relationship anxiety, prostatitis, hyperthyroidism) allows treatment discontinuation once resolved.

PE treatment costs depend on the chosen modality and duration of treatment. All pharmacological options for PE are outpatient treatments with no hospitalization or surgical cost component.

Dapoxetine (Priligy): In India, generic dapoxetine is widely available at $2–8 per tablet (30 mg or 60 mg); brand Priligy is $5–15 per tablet. In the USA, dapoxetine is not FDA-approved and not readily available — men may use compounding pharmacies or import legally; cost approximately $15–40/tablet. UK: Priligy available on prescription, approximately £6–12 per tablet. Germany, Spain: €5–10 per tablet.

Daily SSRIs for PE: generic paroxetine, sertraline, and fluoxetine are extremely low cost — India $5–30/month; USA $20–80/month with insurance, $10–40/month generic without. Topical anesthetic products: EMLA cream (lidocaine/prilocaine) India $8–20/tube; USA $25–60/tube. Fortacin aerosol: Europe approximately €40–80/device (multiple doses). Promescent (lidocaine spray): USA $20–60/bottle.

Psychosexual therapy costs: India $30–100/session at private clinics with certified sex therapists; USA $150–300/session; UK £60–150/session. A typical course involves 6–12 sessions, costing $300–1,200 in India and $1,500–3,600 in the USA. Combination pharmacotherapy plus therapy may cost $500–2,000 annually in India and $3,000–6,000 annually in the USA. No surgical costs are involved; the total economic burden is modest compared to other sexual health treatments.

Complementary and self-directed strategies for PE management include:

• Pelvic floor exercises (Kegel exercises): Strengthening the bulbocavernosus and ischiocavernosus muscles through pelvic floor physiotherapy has demonstrated statistically significant IELT improvement in RCTs, with 82% response rate in one Italian study. A 12-week supervised programme of slow and fast muscle contractions is recommended. A cost-free, risk-free intervention that improves ejaculatory control without medication.
• Mindfulness-based therapy: Mindfulness meditation reduces performance anxiety, hyperarousal, and automatic negative thoughts associated with PE. Weekly mindfulness sessions combined with behavioural techniques show superior outcomes to medication alone in men with psychogenic PE.
• Condom use: Standard latex condoms reduce glans sensitivity modestly; thicker or desensitizing condoms (containing benzocaine) provide additional delay without systemic side effects and no partner numbness risk.
• Psychosexual counselling: Cognitive-behavioral therapy addressing ejaculatory control phobia, relationship conflict, and sexual performance anxiety is particularly effective for acquired PE in the context of a new relationship or stressful life events.